Cargando…

Type 1 T Helper Cell-Based Molecular Subtypes and Signature Are Associated with Clinical Outcome in Pancreatic Ductal Adenocarcinoma

Lymph node metastasis in pancreatic ductal adenocarcinoma (PDAC) is shown to be related with poor prognosis. To construct an immune-related gene prognostic risk model for PDAC and clarify the molecular and immune characteristics and the benefit of immune checkpoint inhibitor (ICI) therapy in prognos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Ran, Zhang, Huihui, Cao, Jianzhong, Qin, Dailei, Deng, Wuguo, Li, Shengping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011157/ https://www.ncbi.nlm.nih.gov/pubmed/35433680 http://dx.doi.org/10.3389/fcell.2022.839893

Ejemplares similares

Sample-Specific Perturbation of Gene Interactions Identifies Pancreatic Cancer Subtypes
por: Wei, Ran, et al.
Publicado: (2022)

An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021)

Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma
por: Bijlsma, Maarten F., et al.
Publicado: (2022)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular
por: Deng, Junyuan, et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models
por: Gündel, Beate, et al.
Publicado: (2021)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
por: Jiang, Weiliang, et al.
Publicado: (2021)

Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming
por: Yang, Sen, et al.
Publicado: (2021)

Retraction: GATA4 regulates inflammation-driven pancreatic ductal adenocarcinoma progression
Publicado: (2023)

A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implications
por: Feng, Zengyu, et al.
Publicado: (2021)

Proteome-Wide Alterations of Asymmetric Arginine Dimethylation Associated With Pancreatic Ductal Adenocarcinoma Pathogenesis
por: Wei, Meijin, et al.
Publicado: (2020)

DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives
por: Stoof, Jojanneke, et al.
Publicado: (2021)

Autophagy Blockage Reduces the Incidence of Pancreatic Ductal Adenocarcinoma in the Context of Mutant Trp53
por: Mainz, Laura, et al.
Publicado: (2022)

Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening
por: Geyer, Marlene, et al.
Publicado: (2021)

Early Diagnosis of Pancreatic Ductal Adenocarcinoma by Combining Relative Expression Orderings With Machine-Learning Method
por: Zhang, Zi-Mei, et al.
Publicado: (2020)

Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma
por: Bose, Mukulika, et al.
Publicado: (2022)

METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma
por: Lu, Liting, et al.
Publicado: (2022)

Mitophagy-mediated molecular subtypes depict the hallmarks of the tumour metabolism and guide precision chemotherapy in pancreatic adenocarcinoma
por: Chen, Hao, et al.
Publicado: (2022)

The Crosstalk Between Malignant Cells and Tumor-Promoting Immune Cells Relevant to Immunotherapy in Pancreatic Ductal Adenocarcinoma
por: Liu, Xuefei, et al.
Publicado: (2022)

Impact of Extracellular pH on Apoptotic and Non-Apoptotic TRAIL-Induced Signaling in Pancreatic Ductal Adenocarcinoma Cells
por: Hagelund, Sofie, et al.
Publicado: (2022)

Clinical Impact of Molecular Subtyping of Pancreatic Cancer
por: Zhou, Xu, et al.
Publicado: (2021)

NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response
por: Hua, Yong-Qiang, et al.
Publicado: (2021)

Single-Cell Transcriptome Reveals the Metabolic and Clinical Features of a Highly Malignant Cell Subpopulation in Pancreatic Ductal Adenocarcinoma
por: Fang, Yangyang, et al.
Publicado: (2022)

Identification and Validation of the Pyroptosis-Related Molecular Subtypes of Lung Adenocarcinoma by Bioinformatics and Machine Learning
por: Liu, Le-Ping, et al.
Publicado: (2021)

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes
por: Hua, Linbin, et al.
Publicado: (2023)

Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer
por: Zhou, Xu, et al.
Publicado: (2023)

The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma
por: Krah, Nathan M, et al.
Publicado: (2015)

RNA m(6)A Demethylase ALKBH5 Protects Against Pancreatic Ductal Adenocarcinoma via Targeting Regulators of Iron Metabolism
por: Huang, Rui, et al.
Publicado: (2021)

Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy
por: Song, Yang, et al.
Publicado: (2020)

Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for mRNA Vaccine Development
por: Xu, Ran, et al.
Publicado: (2022)

Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma
por: Guan, Qiutong, et al.
Publicado: (2022)

Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer
por: Qian, Hao, et al.
Publicado: (2021)

TNF Family–Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma
por: Li, Huihuang, et al.
Publicado: (2022)

Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment
por: Fu, Denggang, et al.
Publicado: (2023)

Identification of Subtypes and a Delayed Graft Function Predictive Signature Based on Ferroptosis in Renal Ischemia-Reperfusion Injury
por: Wei, Xiangling, et al.
Publicado: (2022)

A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma
por: Huo, Junyu, et al.
Publicado: (2021)

Prognostic Nomograms Based on Ground Glass Opacity and Subtype of Lung Adenocarcinoma for Patients with Pathological Stage IA Lung Adenocarcinoma
por: Zhai, Wenyu, et al.
Publicado: (2021)

Identification and validation of the molecular subtype and prognostic signature for clear cell renal cell carcinoma based on neutrophil extracellular traps
por: Quan, Jing, et al.
Publicado: (2022)

Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma
por: Zhang, Fan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2qhlpqldb09bec706if3iu1a4o